nodes	percent_of_prediction	percent_of_DWPC	metapath
Ponatinib—KIT—thymus cancer	0.72	1	CbGaD
Ponatinib—RET—parathyroid gland—thymus cancer	0.0063	0.0613	CbGeAlD
Ponatinib—Ischaemia—Octreotide—thymus cancer	0.00549	0.0698	CcSEcCtD
Ponatinib—Nilotinib—KIT—thymus cancer	0.00318	0.545	CrCbGaD
Ponatinib—FGFR4—hematopoietic system—thymus cancer	0.00302	0.0294	CbGeAlD
Ponatinib—Imatinib—KIT—thymus cancer	0.00266	0.455	CrCbGaD
Ponatinib—Petechiae—Octreotide—thymus cancer	0.00244	0.0309	CcSEcCtD
Ponatinib—Neoplasm malignant—Octreotide—thymus cancer	0.00235	0.0298	CcSEcCtD
Ponatinib—FGFR4—pituitary gland—thymus cancer	0.00224	0.0218	CbGeAlD
Ponatinib—Cellulitis—Octreotide—thymus cancer	0.0022	0.028	CcSEcCtD
Ponatinib—LYN—hematopoietic system—thymus cancer	0.00207	0.0202	CbGeAlD
Ponatinib—FGFR3—hematopoietic system—thymus cancer	0.00206	0.0201	CbGeAlD
Ponatinib—Phosphatase alkaline increased—Octreotide—thymus cancer	0.002	0.0255	CcSEcCtD
Ponatinib—Influenza like illness—Octreotide—thymus cancer	0.00195	0.0247	CcSEcCtD
Ponatinib—RET—neck—thymus cancer	0.00191	0.0186	CbGeAlD
Ponatinib—FGFR3—epithelium—thymus cancer	0.00189	0.0183	CbGeAlD
Ponatinib—Neuropathy—Octreotide—thymus cancer	0.00188	0.0239	CcSEcCtD
Ponatinib—FGFR2—neck—thymus cancer	0.00181	0.0176	CbGeAlD
Ponatinib—BCR—hematopoietic system—thymus cancer	0.00178	0.0174	CbGeAlD
Ponatinib—FLT3—hematopoietic system—thymus cancer	0.00177	0.0172	CbGeAlD
Ponatinib—FGFR4—lung—thymus cancer	0.00176	0.0171	CbGeAlD
Ponatinib—Blood alkaline phosphatase increased—Octreotide—thymus cancer	0.00167	0.0212	CcSEcCtD
Ponatinib—Cardiac failure congestive—Octreotide—thymus cancer	0.0016	0.0204	CcSEcCtD
Ponatinib—Hot flush—Octreotide—thymus cancer	0.00155	0.0198	CcSEcCtD
Ponatinib—Menopausal symptoms—Octreotide—thymus cancer	0.00154	0.0196	CcSEcCtD
Ponatinib—LYN—lymphoid tissue—thymus cancer	0.00146	0.0142	CbGeAlD
Ponatinib—Gastrointestinal haemorrhage—Octreotide—thymus cancer	0.00145	0.0185	CcSEcCtD
Ponatinib—Pain in extremity—Octreotide—thymus cancer	0.00145	0.0185	CcSEcCtD
Ponatinib—KDR—neck—thymus cancer	0.00142	0.0138	CbGeAlD
Ponatinib—RET—hematopoietic system—thymus cancer	0.00142	0.0138	CbGeAlD
Ponatinib—BCR—cardiac atrium—thymus cancer	0.00135	0.0132	CbGeAlD
Ponatinib—Dehydration—Octreotide—thymus cancer	0.00135	0.0172	CcSEcCtD
Ponatinib—FGFR2—hematopoietic system—thymus cancer	0.00135	0.0131	CbGeAlD
Ponatinib—Dry skin—Octreotide—thymus cancer	0.00133	0.0169	CcSEcCtD
Ponatinib—BCR—pituitary gland—thymus cancer	0.00132	0.0129	CbGeAlD
Ponatinib—Nasopharyngitis—Octreotide—thymus cancer	0.0013	0.0165	CcSEcCtD
Ponatinib—RET—epithelium—thymus cancer	0.0013	0.0126	CbGeAlD
Ponatinib—TEK—hematopoietic system—thymus cancer	0.00129	0.0126	CbGeAlD
Ponatinib—Abdominal distension—Octreotide—thymus cancer	0.00127	0.0161	CcSEcCtD
Ponatinib—KIT—neck—thymus cancer	0.00126	0.0123	CbGeAlD
Ponatinib—BCR—lymphoid tissue—thymus cancer	0.00126	0.0122	CbGeAlD
Ponatinib—FLT3—lymphoid tissue—thymus cancer	0.00125	0.0121	CbGeAlD
Ponatinib—FGFR2—epithelium—thymus cancer	0.00123	0.012	CbGeAlD
Ponatinib—Pancreatitis—Octreotide—thymus cancer	0.00123	0.0157	CcSEcCtD
Ponatinib—FGFR1—cardiac atrium—thymus cancer	0.00121	0.0117	CbGeAlD
Ponatinib—Abdominal discomfort—Octreotide—thymus cancer	0.00121	0.0153	CcSEcCtD
Ponatinib—FGFR4—lymph node—thymus cancer	0.0012	0.0117	CbGeAlD
Ponatinib—FGFR3—lung—thymus cancer	0.0012	0.0117	CbGeAlD
Ponatinib—TEK—epithelium—thymus cancer	0.00118	0.0115	CbGeAlD
Ponatinib—FGFR1—pituitary gland—thymus cancer	0.00118	0.0115	CbGeAlD
Ponatinib—PDGFRA—hematopoietic system—thymus cancer	0.00117	0.0114	CbGeAlD
Ponatinib—Upper respiratory tract infection—Octreotide—thymus cancer	0.00117	0.0148	CcSEcCtD
Ponatinib—SRC—hematopoietic system—thymus cancer	0.00115	0.0112	CbGeAlD
Ponatinib—BCR—bone marrow—thymus cancer	0.00114	0.0111	CbGeAlD
Ponatinib—BCR—thyroid gland—thymus cancer	0.00114	0.0111	CbGeAlD
Ponatinib—Weight decreased—Octreotide—thymus cancer	0.00114	0.0144	CcSEcCtD
Ponatinib—FLT3—bone marrow—thymus cancer	0.00114	0.0111	CbGeAlD
Ponatinib—Hyperglycaemia—Octreotide—thymus cancer	0.00113	0.0144	CcSEcCtD
Ponatinib—Pneumonia—Octreotide—thymus cancer	0.00113	0.0143	CcSEcCtD
Ponatinib—Neuropathy peripheral—Octreotide—thymus cancer	0.0011	0.014	CcSEcCtD
Ponatinib—Jaundice—Octreotide—thymus cancer	0.00109	0.0139	CcSEcCtD
Ponatinib—Urinary tract infection—Octreotide—thymus cancer	0.00109	0.0138	CcSEcCtD
Ponatinib—Hepatobiliary disease—Octreotide—thymus cancer	0.00106	0.0135	CcSEcCtD
Ponatinib—KDR—hematopoietic system—thymus cancer	0.00106	0.0103	CbGeAlD
Ponatinib—Epistaxis—Octreotide—thymus cancer	0.00106	0.0134	CcSEcCtD
Ponatinib—RET—pituitary gland—thymus cancer	0.00105	0.0103	CbGeAlD
Ponatinib—SRC—epithelium—thymus cancer	0.00105	0.0102	CbGeAlD
Ponatinib—BCR—lung—thymus cancer	0.00104	0.0101	CbGeAlD
Ponatinib—FLT3—lung—thymus cancer	0.00103	0.01	CbGeAlD
Ponatinib—FGFR1—thyroid gland—thymus cancer	0.00102	0.00988	CbGeAlD
Ponatinib—Hypoaesthesia—Octreotide—thymus cancer	0.001	0.0127	CcSEcCtD
Ponatinib—RET—lymphoid tissue—thymus cancer	0.001	0.00973	CbGeAlD
Ponatinib—Oedema peripheral—Octreotide—thymus cancer	0.000991	0.0126	CcSEcCtD
Ponatinib—TEK—cardiac atrium—thymus cancer	0.000983	0.00956	CbGeAlD
Ponatinib—Visual impairment—Octreotide—thymus cancer	0.00097	0.0123	CcSEcCtD
Ponatinib—KDR—epithelium—thymus cancer	0.000967	0.00941	CbGeAlD
Ponatinib—TEK—pituitary gland—thymus cancer	0.00096	0.00934	CbGeAlD
Ponatinib—KIT—hematopoietic system—thymus cancer	0.000937	0.00912	CbGeAlD
Ponatinib—Flushing—Octreotide—thymus cancer	0.000934	0.0119	CcSEcCtD
Ponatinib—Cardiac disorder—Octreotide—thymus cancer	0.000934	0.0119	CcSEcCtD
Ponatinib—FGFR1—lung—thymus cancer	0.000922	0.00897	CbGeAlD
Ponatinib—TEK—lymphoid tissue—thymus cancer	0.000911	0.00886	CbGeAlD
Ponatinib—LCK—bone marrow—thymus cancer	0.000911	0.00886	CbGeAlD
Ponatinib—RET—thyroid gland—thymus cancer	0.000909	0.00884	CbGeAlD
Ponatinib—LCK—thyroid gland—thymus cancer	0.000909	0.00884	CbGeAlD
Ponatinib—Arrhythmia—Octreotide—thymus cancer	0.000899	0.0114	CcSEcCtD
Ponatinib—Alopecia—Octreotide—thymus cancer	0.000889	0.0113	CcSEcCtD
Ponatinib—Mental disorder—Octreotide—thymus cancer	0.000882	0.0112	CcSEcCtD
Ponatinib—Erythema—Octreotide—thymus cancer	0.000876	0.0111	CcSEcCtD
Ponatinib—Malnutrition—Octreotide—thymus cancer	0.000876	0.0111	CcSEcCtD
Ponatinib—SRC—cardiac atrium—thymus cancer	0.000873	0.00849	CbGeAlD
Ponatinib—FGFR2—thyroid gland—thymus cancer	0.000863	0.0084	CbGeAlD
Ponatinib—KIT—epithelium—thymus cancer	0.000857	0.00834	CbGeAlD
Ponatinib—Back pain—Octreotide—thymus cancer	0.000847	0.0108	CcSEcCtD
Ponatinib—Muscle spasms—Octreotide—thymus cancer	0.000842	0.0107	CcSEcCtD
Ponatinib—TEK—thyroid gland—thymus cancer	0.000828	0.00805	CbGeAlD
Ponatinib—PDGFRA—lymphoid tissue—thymus cancer	0.000826	0.00803	CbGeAlD
Ponatinib—Vision blurred—Octreotide—thymus cancer	0.000825	0.0105	CcSEcCtD
Ponatinib—LCK—lung—thymus cancer	0.000825	0.00803	CbGeAlD
Ponatinib—ABL1—hematopoietic system—thymus cancer	0.000816	0.00794	CbGeAlD
Ponatinib—Anaemia—Octreotide—thymus cancer	0.00081	0.0103	CcSEcCtD
Ponatinib—SRC—lymphoid tissue—thymus cancer	0.00081	0.00788	CbGeAlD
Ponatinib—KDR—cardiac atrium—thymus cancer	0.000803	0.00781	CbGeAlD
Ponatinib—KDR—pituitary gland—thymus cancer	0.000785	0.00763	CbGeAlD
Ponatinib—FGFR2—lung—thymus cancer	0.000784	0.00763	CbGeAlD
Ponatinib—Cough—Octreotide—thymus cancer	0.000764	0.00971	CcSEcCtD
Ponatinib—Hypertension—Octreotide—thymus cancer	0.000756	0.00961	CcSEcCtD
Ponatinib—TEK—lung—thymus cancer	0.000752	0.00731	CbGeAlD
Ponatinib—PDGFRA—thyroid gland—thymus cancer	0.00075	0.00729	CbGeAlD
Ponatinib—Myalgia—Octreotide—thymus cancer	0.000746	0.00947	CcSEcCtD
Ponatinib—Arthralgia—Octreotide—thymus cancer	0.000746	0.00947	CcSEcCtD
Ponatinib—KDR—lymphoid tissue—thymus cancer	0.000745	0.00724	CbGeAlD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Octreotide—thymus cancer	0.000741	0.00941	CcSEcCtD
Ponatinib—SRC—thyroid gland—thymus cancer	0.000735	0.00715	CbGeAlD
Ponatinib—Dry mouth—Octreotide—thymus cancer	0.000729	0.00927	CcSEcCtD
Ponatinib—Oedema—Octreotide—thymus cancer	0.000715	0.00908	CcSEcCtD
Ponatinib—Infection—Octreotide—thymus cancer	0.00071	0.00902	CcSEcCtD
Ponatinib—BCR—lymph node—thymus cancer	0.000709	0.0069	CbGeAlD
Ponatinib—FLT3—lymph node—thymus cancer	0.000704	0.00685	CbGeAlD
Ponatinib—Nervous system disorder—Octreotide—thymus cancer	0.000701	0.00891	CcSEcCtD
Ponatinib—Thrombocytopenia—Octreotide—thymus cancer	0.0007	0.00889	CcSEcCtD
Ponatinib—KIT—pituitary gland—thymus cancer	0.000695	0.00676	CbGeAlD
Ponatinib—Skin disorder—Octreotide—thymus cancer	0.000694	0.00882	CcSEcCtD
Ponatinib—Hyperhidrosis—Octreotide—thymus cancer	0.000691	0.00878	CcSEcCtD
Ponatinib—PDGFRA—lung—thymus cancer	0.000681	0.00663	CbGeAlD
Ponatinib—KDR—bone marrow—thymus cancer	0.000678	0.0066	CbGeAlD
Ponatinib—KDR—thyroid gland—thymus cancer	0.000676	0.00658	CbGeAlD
Ponatinib—SRC—lung—thymus cancer	0.000668	0.0065	CbGeAlD
Ponatinib—KIT—lymphoid tissue—thymus cancer	0.00066	0.00642	CbGeAlD
Ponatinib—Musculoskeletal discomfort—Octreotide—thymus cancer	0.000651	0.00827	CcSEcCtD
Ponatinib—Insomnia—Octreotide—thymus cancer	0.000647	0.00821	CcSEcCtD
Ponatinib—Paraesthesia—Octreotide—thymus cancer	0.000642	0.00815	CcSEcCtD
Ponatinib—Dyspnoea—Octreotide—thymus cancer	0.000637	0.0081	CcSEcCtD
Ponatinib—FGFR1—lymph node—thymus cancer	0.000631	0.00614	CbGeAlD
Ponatinib—Dyspepsia—Octreotide—thymus cancer	0.000629	0.00799	CcSEcCtD
Ponatinib—Decreased appetite—Octreotide—thymus cancer	0.000621	0.00789	CcSEcCtD
Ponatinib—ABL1—cardiac atrium—thymus cancer	0.00062	0.00603	CbGeAlD
Ponatinib—Gastrointestinal disorder—Octreotide—thymus cancer	0.000617	0.00784	CcSEcCtD
Ponatinib—Fatigue—Octreotide—thymus cancer	0.000616	0.00783	CcSEcCtD
Ponatinib—KDR—lung—thymus cancer	0.000614	0.00598	CbGeAlD
Ponatinib—Constipation—Octreotide—thymus cancer	0.000611	0.00777	CcSEcCtD
Ponatinib—Pain—Octreotide—thymus cancer	0.000611	0.00777	CcSEcCtD
Ponatinib—ABL1—pituitary gland—thymus cancer	0.000605	0.00589	CbGeAlD
Ponatinib—KIT—bone marrow—thymus cancer	0.000601	0.00585	CbGeAlD
Ponatinib—KIT—thyroid gland—thymus cancer	0.000599	0.00583	CbGeAlD
Ponatinib—Gastrointestinal pain—Octreotide—thymus cancer	0.000585	0.00743	CcSEcCtD
Ponatinib—ABL1—lymphoid tissue—thymus cancer	0.000574	0.00559	CbGeAlD
Ponatinib—Body temperature increased—Octreotide—thymus cancer	0.000565	0.00718	CcSEcCtD
Ponatinib—Abdominal pain—Octreotide—thymus cancer	0.000565	0.00718	CcSEcCtD
Ponatinib—LCK—lymph node—thymus cancer	0.000564	0.00549	CbGeAlD
Ponatinib—RET—lymph node—thymus cancer	0.000564	0.00549	CbGeAlD
Ponatinib—KIT—lung—thymus cancer	0.000544	0.0053	CbGeAlD
Ponatinib—CYP2C8—hematopoietic system—thymus cancer	0.000529	0.00515	CbGeAlD
Ponatinib—ABL1—bone marrow—thymus cancer	0.000523	0.00509	CbGeAlD
Ponatinib—ABL1—thyroid gland—thymus cancer	0.000522	0.00508	CbGeAlD
Ponatinib—TEK—lymph node—thymus cancer	0.000514	0.005	CbGeAlD
Ponatinib—Asthenia—Octreotide—thymus cancer	0.000513	0.00652	CcSEcCtD
Ponatinib—Pruritus—Octreotide—thymus cancer	0.000506	0.00643	CcSEcCtD
Ponatinib—Diarrhoea—Octreotide—thymus cancer	0.000489	0.00621	CcSEcCtD
Ponatinib—CYP3A5—hematopoietic system—thymus cancer	0.000478	0.00465	CbGeAlD
Ponatinib—ABL1—lung—thymus cancer	0.000474	0.00461	CbGeAlD
Ponatinib—Dizziness—Octreotide—thymus cancer	0.000473	0.00601	CcSEcCtD
Ponatinib—PDGFRA—lymph node—thymus cancer	0.000466	0.00453	CbGeAlD
Ponatinib—SRC—lymph node—thymus cancer	0.000457	0.00444	CbGeAlD
Ponatinib—Vomiting—Octreotide—thymus cancer	0.000455	0.00577	CcSEcCtD
Ponatinib—Rash—Octreotide—thymus cancer	0.000451	0.00573	CcSEcCtD
Ponatinib—Dermatitis—Octreotide—thymus cancer	0.00045	0.00572	CcSEcCtD
Ponatinib—Headache—Octreotide—thymus cancer	0.000448	0.00569	CcSEcCtD
Ponatinib—Nausea—Octreotide—thymus cancer	0.000425	0.00539	CcSEcCtD
Ponatinib—KDR—lymph node—thymus cancer	0.00042	0.00409	CbGeAlD
Ponatinib—CYP2C8—pituitary gland—thymus cancer	0.000393	0.00382	CbGeAlD
Ponatinib—ABCG2—pituitary gland—thymus cancer	0.000382	0.00371	CbGeAlD
Ponatinib—KIT—lymph node—thymus cancer	0.000372	0.00362	CbGeAlD
Ponatinib—CYP3A4—hematopoietic system—thymus cancer	0.000358	0.00349	CbGeAlD
Ponatinib—CYP2D6—hematopoietic system—thymus cancer	0.000353	0.00343	CbGeAlD
Ponatinib—ABCG2—bone marrow—thymus cancer	0.00033	0.00321	CbGeAlD
Ponatinib—ABCG2—thyroid gland—thymus cancer	0.000329	0.0032	CbGeAlD
Ponatinib—ABL1—lymph node—thymus cancer	0.000324	0.00315	CbGeAlD
Ponatinib—ABCG2—lung—thymus cancer	0.000299	0.00291	CbGeAlD
Ponatinib—CYP3A5—lung—thymus cancer	0.000277	0.0027	CbGeAlD
Ponatinib—ABCB1—hematopoietic system—thymus cancer	0.000254	0.00247	CbGeAlD
Ponatinib—ABCB1—epithelium—thymus cancer	0.000232	0.00226	CbGeAlD
Ponatinib—ABCG2—lymph node—thymus cancer	0.000204	0.00199	CbGeAlD
Ponatinib—ABCB1—pituitary gland—thymus cancer	0.000188	0.00183	CbGeAlD
Ponatinib—ABCB1—lymphoid tissue—thymus cancer	0.000179	0.00174	CbGeAlD
Ponatinib—ABCB1—bone marrow—thymus cancer	0.000163	0.00158	CbGeAlD
Ponatinib—ABCB1—thyroid gland—thymus cancer	0.000162	0.00158	CbGeAlD
Ponatinib—ABCB1—lung—thymus cancer	0.000147	0.00143	CbGeAlD
Ponatinib—ABCB1—lymph node—thymus cancer	0.000101	0.000981	CbGeAlD
Ponatinib—KIT—B Cell Activation—AKT1—thymus cancer	4.82e-05	0.00052	CbGpPWpGaD
Ponatinib—SRC—ErbB1 downstream signaling—AKT1—thymus cancer	4.79e-05	0.000517	CbGpPWpGaD
Ponatinib—FGFR4—Immune System—CD4—thymus cancer	4.73e-05	0.00051	CbGpPWpGaD
Ponatinib—SRC—TGF-beta Signaling Pathway—TP53—thymus cancer	4.73e-05	0.00051	CbGpPWpGaD
Ponatinib—SRC—VEGFA-VEGFR2 Pathway—AKT1—thymus cancer	4.72e-05	0.000509	CbGpPWpGaD
Ponatinib—FGFR2—NGF signalling via TRKA from the plasma membrane—AKT1—thymus cancer	4.7e-05	0.000507	CbGpPWpGaD
Ponatinib—PDGFRA—Focal Adhesion—AKT1—thymus cancer	4.66e-05	0.000503	CbGpPWpGaD
Ponatinib—FGFR1—Integrated Pancreatic Cancer Pathway—AKT1—thymus cancer	4.65e-05	0.000502	CbGpPWpGaD
Ponatinib—ABL1—EGF/EGFR Signaling Pathway—AKT1—thymus cancer	4.65e-05	0.000501	CbGpPWpGaD
Ponatinib—LCK—Adaptive Immune System—CD8A—thymus cancer	4.64e-05	0.000501	CbGpPWpGaD
Ponatinib—PDGFRA—Integrated Pancreatic Cancer Pathway—AKT1—thymus cancer	4.64e-05	0.0005	CbGpPWpGaD
Ponatinib—KIT—NGF signalling via TRKA from the plasma membrane—AKT1—thymus cancer	4.61e-05	0.000498	CbGpPWpGaD
Ponatinib—FGFR1—B Cell Activation—AKT1—thymus cancer	4.58e-05	0.000494	CbGpPWpGaD
Ponatinib—FGFR3—Immune System—KIT—thymus cancer	4.57e-05	0.000493	CbGpPWpGaD
Ponatinib—PDGFRA—B Cell Activation—AKT1—thymus cancer	4.56e-05	0.000492	CbGpPWpGaD
Ponatinib—LCK—Cytokine Signaling in Immune system—IL2—thymus cancer	4.56e-05	0.000491	CbGpPWpGaD
Ponatinib—SRC—Signaling by VEGF—AKT1—thymus cancer	4.46e-05	0.000481	CbGpPWpGaD
Ponatinib—LYN—Innate Immune System—KIT—thymus cancer	4.43e-05	0.000478	CbGpPWpGaD
Ponatinib—ABL1—Innate Immune System—KIT—thymus cancer	4.41e-05	0.000475	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—MAML2—thymus cancer	4.41e-05	0.000475	CbGpPWpGaD
Ponatinib—FGFR1—NGF signalling via TRKA from the plasma membrane—AKT1—thymus cancer	4.38e-05	0.000472	CbGpPWpGaD
Ponatinib—PDGFRA—NGF signalling via TRKA from the plasma membrane—AKT1—thymus cancer	4.37e-05	0.000471	CbGpPWpGaD
Ponatinib—FGFR4—Disease—CD4—thymus cancer	4.37e-05	0.000471	CbGpPWpGaD
Ponatinib—FGFR4—Immune System—IL2—thymus cancer	4.35e-05	0.000469	CbGpPWpGaD
Ponatinib—LYN—Fc epsilon receptor (FCERI) signaling—AKT1—thymus cancer	4.35e-05	0.000469	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—MAML2—thymus cancer	4.33e-05	0.000467	CbGpPWpGaD
Ponatinib—LCK—Signaling by SCF-KIT—AKT1—thymus cancer	4.28e-05	0.000461	CbGpPWpGaD
Ponatinib—LYN—Adaptive Immune System—KIT—thymus cancer	4.25e-05	0.000459	CbGpPWpGaD
Ponatinib—LCK—Disease—MAML2—thymus cancer	4.23e-05	0.000456	CbGpPWpGaD
Ponatinib—FGFR3—Disease—KIT—thymus cancer	4.22e-05	0.000455	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—CD8A—thymus cancer	4.19e-05	0.000452	CbGpPWpGaD
Ponatinib—FGFR2—Innate Immune System—CD4—thymus cancer	4.13e-05	0.000446	CbGpPWpGaD
Ponatinib—KIT—Immune System—CD8A—thymus cancer	4.11e-05	0.000444	CbGpPWpGaD
Ponatinib—ABCB1—HIF-1-alpha transcription factor network—AKT1—thymus cancer	4.11e-05	0.000443	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—CD8A—thymus cancer	4.11e-05	0.000443	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—MAML2—thymus cancer	4.11e-05	0.000443	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—MAML2—thymus cancer	4.1e-05	0.000442	CbGpPWpGaD
Ponatinib—LCK—Downstream signaling of activated FGFR—AKT1—thymus cancer	4.09e-05	0.000441	CbGpPWpGaD
Ponatinib—ABL1—Integrated Pancreatic Cancer Pathway—AKT1—thymus cancer	4.07e-05	0.000439	CbGpPWpGaD
Ponatinib—KIT—Innate Immune System—CD4—thymus cancer	4.06e-05	0.000438	CbGpPWpGaD
Ponatinib—FGFR4—Innate Immune System—AKT1—thymus cancer	4.05e-05	0.000437	CbGpPWpGaD
Ponatinib—LCK—Signaling by ERBB4—AKT1—thymus cancer	4.03e-05	0.000434	CbGpPWpGaD
Ponatinib—LYN—B Cell Activation—AKT1—thymus cancer	4.03e-05	0.000434	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—KIT—thymus cancer	4e-05	0.000431	CbGpPWpGaD
Ponatinib—BCR—Signaling Pathways—IL2—thymus cancer	3.99e-05	0.000431	CbGpPWpGaD
Ponatinib—SRC—TGF-beta Signaling Pathway—AKT1—thymus cancer	3.99e-05	0.00043	CbGpPWpGaD
Ponatinib—FGFR2—Adaptive Immune System—CD4—thymus cancer	3.97e-05	0.000428	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—CD8A—thymus cancer	3.9e-05	0.000421	CbGpPWpGaD
Ponatinib—KIT—Adaptive Immune System—CD4—thymus cancer	3.9e-05	0.00042	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—CD8A—thymus cancer	3.89e-05	0.00042	CbGpPWpGaD
Ponatinib—FGFR4—Adaptive Immune System—AKT1—thymus cancer	3.89e-05	0.00042	CbGpPWpGaD
Ponatinib—FGFR1—Innate Immune System—CD4—thymus cancer	3.85e-05	0.000415	CbGpPWpGaD
Ponatinib—LCK—Downstream signal transduction—AKT1—thymus cancer	3.85e-05	0.000415	CbGpPWpGaD
Ponatinib—PDGFRA—Innate Immune System—CD4—thymus cancer	3.84e-05	0.000414	CbGpPWpGaD
Ponatinib—LCK—Signaling by FGFR—AKT1—thymus cancer	3.83e-05	0.000413	CbGpPWpGaD
Ponatinib—LCK—Signaling by ERBB2—AKT1—thymus cancer	3.81e-05	0.000411	CbGpPWpGaD
Ponatinib—LCK—DAP12 signaling—AKT1—thymus cancer	3.79e-05	0.000409	CbGpPWpGaD
Ponatinib—SRC—Signaling by SCF-KIT—AKT1—thymus cancer	3.79e-05	0.000408	CbGpPWpGaD
Ponatinib—SRC—Disease—MAML2—thymus cancer	3.74e-05	0.000404	CbGpPWpGaD
Ponatinib—LCK—Downstream signaling events of B Cell Receptor (BCR)—AKT1—thymus cancer	3.73e-05	0.000403	CbGpPWpGaD
Ponatinib—SRC—BDNF signaling pathway—AKT1—thymus cancer	3.72e-05	0.000402	CbGpPWpGaD
Ponatinib—FGFR1—Adaptive Immune System—CD4—thymus cancer	3.7e-05	0.000399	CbGpPWpGaD
Ponatinib—PDGFRA—Adaptive Immune System—CD4—thymus cancer	3.69e-05	0.000398	CbGpPWpGaD
Ponatinib—LYN—Platelet activation, signaling and aggregation—AKT1—thymus cancer	3.64e-05	0.000393	CbGpPWpGaD
Ponatinib—LCK—Innate Immune System—KIT—thymus cancer	3.63e-05	0.000392	CbGpPWpGaD
Ponatinib—FGFR2—Signaling by NGF—AKT1—thymus cancer	3.61e-05	0.00039	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—MAML2—thymus cancer	3.61e-05	0.00039	CbGpPWpGaD
Ponatinib—LCK—DAP12 interactions—AKT1—thymus cancer	3.56e-05	0.000385	CbGpPWpGaD
Ponatinib—LCK—Fc epsilon receptor (FCERI) signaling—AKT1—thymus cancer	3.56e-05	0.000385	CbGpPWpGaD
Ponatinib—LCK—Signaling by FGFR in disease—AKT1—thymus cancer	3.56e-05	0.000385	CbGpPWpGaD
Ponatinib—KIT—Signaling by NGF—AKT1—thymus cancer	3.55e-05	0.000383	CbGpPWpGaD
Ponatinib—LCK—Signaling by EGFR—AKT1—thymus cancer	3.53e-05	0.000381	CbGpPWpGaD
Ponatinib—SRC—Integrated Pancreatic Cancer Pathway—TP53—thymus cancer	3.52e-05	0.000379	CbGpPWpGaD
Ponatinib—LCK—Signaling by EGFR in Cancer—AKT1—thymus cancer	3.5e-05	0.000378	CbGpPWpGaD
Ponatinib—FGFR3—Immune System—CD4—thymus cancer	3.5e-05	0.000377	CbGpPWpGaD
Ponatinib—LCK—Signaling by PDGF—AKT1—thymus cancer	3.49e-05	0.000376	CbGpPWpGaD
Ponatinib—LCK—Adaptive Immune System—KIT—thymus cancer	3.49e-05	0.000376	CbGpPWpGaD
Ponatinib—LYN—Hemostasis—IL2—thymus cancer	3.46e-05	0.000373	CbGpPWpGaD
Ponatinib—ABL1—Hemostasis—IL2—thymus cancer	3.45e-05	0.000372	CbGpPWpGaD
Ponatinib—LYN—Immune System—CD8A—thymus cancer	3.43e-05	0.000371	CbGpPWpGaD
Ponatinib—ABL1—Immune System—CD8A—thymus cancer	3.42e-05	0.000369	CbGpPWpGaD
Ponatinib—SRC—Downstream signal transduction—AKT1—thymus cancer	3.4e-05	0.000367	CbGpPWpGaD
Ponatinib—SRC—Signaling by FGFR—AKT1—thymus cancer	3.39e-05	0.000365	CbGpPWpGaD
Ponatinib—SRC—EGF/EGFR Signaling Pathway—AKT1—thymus cancer	3.39e-05	0.000365	CbGpPWpGaD
Ponatinib—LYN—Innate Immune System—CD4—thymus cancer	3.39e-05	0.000365	CbGpPWpGaD
Ponatinib—ABL1—Innate Immune System—CD4—thymus cancer	3.37e-05	0.000364	CbGpPWpGaD
Ponatinib—SRC—Signaling by ERBB2—AKT1—thymus cancer	3.37e-05	0.000364	CbGpPWpGaD
Ponatinib—FGFR1—Signaling by NGF—AKT1—thymus cancer	3.37e-05	0.000363	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling by NGF—AKT1—thymus cancer	3.36e-05	0.000362	CbGpPWpGaD
Ponatinib—LCK—B Cell Activation—AKT1—thymus cancer	3.3e-05	0.000356	CbGpPWpGaD
Ponatinib—LYN—Adaptive Immune System—CD4—thymus cancer	3.25e-05	0.000351	CbGpPWpGaD
Ponatinib—FGFR3—Disease—CD4—thymus cancer	3.23e-05	0.000348	CbGpPWpGaD
Ponatinib—FGFR3—Immune System—IL2—thymus cancer	3.22e-05	0.000347	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—KIT—thymus cancer	3.21e-05	0.000347	CbGpPWpGaD
Ponatinib—LCK—NGF signalling via TRKA from the plasma membrane—AKT1—thymus cancer	3.16e-05	0.000341	CbGpPWpGaD
Ponatinib—SRC—Signaling by FGFR in disease—AKT1—thymus cancer	3.16e-05	0.00034	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—KIT—thymus cancer	3.15e-05	0.000339	CbGpPWpGaD
Ponatinib—SRC—Signaling by EGFR—AKT1—thymus cancer	3.13e-05	0.000337	CbGpPWpGaD
Ponatinib—SRC—Signaling by EGFR in Cancer—AKT1—thymus cancer	3.1e-05	0.000334	CbGpPWpGaD
Ponatinib—BCR—Disease—AKT1—thymus cancer	3.09e-05	0.000334	CbGpPWpGaD
Ponatinib—SRC—Signaling by PDGF—AKT1—thymus cancer	3.09e-05	0.000333	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—KIT—thymus cancer	3.09e-05	0.000333	CbGpPWpGaD
Ponatinib—FGFR3—Innate Immune System—AKT1—thymus cancer	3e-05	0.000323	CbGpPWpGaD
Ponatinib—LCK—Platelet activation, signaling and aggregation—AKT1—thymus cancer	2.98e-05	0.000322	CbGpPWpGaD
Ponatinib—SRC—Focal Adhesion—AKT1—thymus cancer	2.98e-05	0.000322	CbGpPWpGaD
Ponatinib—SRC—Membrane Trafficking—AKT1—thymus cancer	2.98e-05	0.000322	CbGpPWpGaD
Ponatinib—SRC—Integrated Pancreatic Cancer Pathway—AKT1—thymus cancer	2.97e-05	0.00032	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—MAML2—thymus cancer	2.96e-05	0.000319	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—KIT—thymus cancer	2.96e-05	0.000319	CbGpPWpGaD
Ponatinib—KDR—Developmental Biology—AKT1—thymus cancer	2.96e-05	0.000319	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—KIT—thymus cancer	2.93e-05	0.000316	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—KIT—thymus cancer	2.92e-05	0.000315	CbGpPWpGaD
Ponatinib—FGFR2—Disease—KIT—thymus cancer	2.9e-05	0.000313	CbGpPWpGaD
Ponatinib—FGFR3—Adaptive Immune System—AKT1—thymus cancer	2.88e-05	0.00031	CbGpPWpGaD
Ponatinib—LCK—Hemostasis—IL2—thymus cancer	2.84e-05	0.000306	CbGpPWpGaD
Ponatinib—LCK—Immune System—CD8A—thymus cancer	2.82e-05	0.000304	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—IL2—thymus cancer	2.81e-05	0.000303	CbGpPWpGaD
Ponatinib—SRC—NGF signalling via TRKA from the plasma membrane—AKT1—thymus cancer	2.8e-05	0.000302	CbGpPWpGaD
Ponatinib—LCK—Innate Immune System—CD4—thymus cancer	2.78e-05	0.000299	CbGpPWpGaD
Ponatinib—FGFR1—Disease—KIT—thymus cancer	2.71e-05	0.000292	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—KIT—thymus cancer	2.7e-05	0.000291	CbGpPWpGaD
Ponatinib—LCK—Adaptive Immune System—CD4—thymus cancer	2.67e-05	0.000288	CbGpPWpGaD
Ponatinib—SRC—Platelet activation, signaling and aggregation—AKT1—thymus cancer	2.64e-05	0.000285	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MAML2—thymus cancer	2.62e-05	0.000283	CbGpPWpGaD
Ponatinib—LYN—Immune System—KIT—thymus cancer	2.58e-05	0.000278	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—KIT—thymus cancer	2.58e-05	0.000278	CbGpPWpGaD
Ponatinib—ABL1—Immune System—KIT—thymus cancer	2.57e-05	0.000277	CbGpPWpGaD
Ponatinib—BCR—Signaling Pathways—TP53—thymus cancer	2.56e-05	0.000277	CbGpPWpGaD
Ponatinib—SRC—Hemostasis—IL2—thymus cancer	2.51e-05	0.000271	CbGpPWpGaD
Ponatinib—SRC—Immune System—CD8A—thymus cancer	2.49e-05	0.000269	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—CD4—thymus cancer	2.46e-05	0.000265	CbGpPWpGaD
Ponatinib—LCK—Signaling by NGF—AKT1—thymus cancer	2.43e-05	0.000262	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—CD4—thymus cancer	2.41e-05	0.00026	CbGpPWpGaD
Ponatinib—KIT—Immune System—CD4—thymus cancer	2.36e-05	0.000255	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—CD4—thymus cancer	2.36e-05	0.000255	CbGpPWpGaD
Ponatinib—FGFR4—Immune System—AKT1—thymus cancer	2.36e-05	0.000254	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—CD4—thymus cancer	2.24e-05	0.000242	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—CD4—thymus cancer	2.24e-05	0.000241	CbGpPWpGaD
Ponatinib—LYN—Hemostasis—TP53—thymus cancer	2.22e-05	0.00024	CbGpPWpGaD
Ponatinib—FGFR2—Disease—CD4—thymus cancer	2.22e-05	0.00024	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—IL2—thymus cancer	2.21e-05	0.000239	CbGpPWpGaD
Ponatinib—ABL1—Hemostasis—TP53—thymus cancer	2.21e-05	0.000239	CbGpPWpGaD
Ponatinib—KIT—Disease—CD4—thymus cancer	2.18e-05	0.000235	CbGpPWpGaD
Ponatinib—FGFR4—Disease—AKT1—thymus cancer	2.18e-05	0.000235	CbGpPWpGaD
Ponatinib—FGFR1—Developmental Biology—AKT1—thymus cancer	2.17e-05	0.000235	CbGpPWpGaD
Ponatinib—KIT—Immune System—IL2—thymus cancer	2.17e-05	0.000235	CbGpPWpGaD
Ponatinib—BCR—Signaling Pathways—AKT1—thymus cancer	2.17e-05	0.000234	CbGpPWpGaD
Ponatinib—SRC—Signaling by NGF—AKT1—thymus cancer	2.15e-05	0.000232	CbGpPWpGaD
Ponatinib—LCK—Immune System—KIT—thymus cancer	2.11e-05	0.000228	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—IL2—thymus cancer	2.08e-05	0.000224	CbGpPWpGaD
Ponatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—thymus cancer	2.08e-05	0.000224	CbGpPWpGaD
Ponatinib—FGFR1—Disease—CD4—thymus cancer	2.07e-05	0.000223	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—CD4—thymus cancer	2.06e-05	0.000223	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—IL2—thymus cancer	2.06e-05	0.000223	CbGpPWpGaD
Ponatinib—FGFR2—Innate Immune System—AKT1—thymus cancer	2.06e-05	0.000222	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—IL2—thymus cancer	2.06e-05	0.000222	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—KIT—thymus cancer	2.03e-05	0.000219	CbGpPWpGaD
Ponatinib—KIT—Innate Immune System—AKT1—thymus cancer	2.02e-05	0.000218	CbGpPWpGaD
Ponatinib—FGFR2—Adaptive Immune System—AKT1—thymus cancer	1.98e-05	0.000213	CbGpPWpGaD
Ponatinib—LYN—Immune System—CD4—thymus cancer	1.97e-05	0.000213	CbGpPWpGaD
Ponatinib—ABL1—Immune System—CD4—thymus cancer	1.96e-05	0.000212	CbGpPWpGaD
Ponatinib—LCK—Disease—KIT—thymus cancer	1.95e-05	0.000211	CbGpPWpGaD
Ponatinib—KIT—Adaptive Immune System—AKT1—thymus cancer	1.94e-05	0.00021	CbGpPWpGaD
Ponatinib—FGFR1—Innate Immune System—AKT1—thymus cancer	1.92e-05	0.000207	CbGpPWpGaD
Ponatinib—PDGFRA—Innate Immune System—AKT1—thymus cancer	1.92e-05	0.000207	CbGpPWpGaD
Ponatinib—LYN—Developmental Biology—AKT1—thymus cancer	1.91e-05	0.000206	CbGpPWpGaD
Ponatinib—ABL1—Developmental Biology—AKT1—thymus cancer	1.9e-05	0.000205	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—KIT—thymus cancer	1.9e-05	0.000204	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—KIT—thymus cancer	1.89e-05	0.000204	CbGpPWpGaD
Ponatinib—LYN—Hemostasis—AKT1—thymus cancer	1.88e-05	0.000202	CbGpPWpGaD
Ponatinib—SRC—Immune System—KIT—thymus cancer	1.87e-05	0.000202	CbGpPWpGaD
Ponatinib—ABL1—Hemostasis—AKT1—thymus cancer	1.87e-05	0.000202	CbGpPWpGaD
Ponatinib—FGFR1—Adaptive Immune System—AKT1—thymus cancer	1.84e-05	0.000199	CbGpPWpGaD
Ponatinib—PDGFRA—Adaptive Immune System—AKT1—thymus cancer	1.84e-05	0.000198	CbGpPWpGaD
Ponatinib—LCK—Hemostasis—TP53—thymus cancer	1.82e-05	0.000197	CbGpPWpGaD
Ponatinib—LYN—Immune System—IL2—thymus cancer	1.82e-05	0.000196	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—IL2—thymus cancer	1.81e-05	0.000196	CbGpPWpGaD
Ponatinib—ABL1—Immune System—IL2—thymus cancer	1.81e-05	0.000195	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—TP53—thymus cancer	1.81e-05	0.000195	CbGpPWpGaD
Ponatinib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—thymus cancer	1.76e-05	0.00019	CbGpPWpGaD
Ponatinib—FGFR3—Immune System—AKT1—thymus cancer	1.75e-05	0.000188	CbGpPWpGaD
Ponatinib—SRC—Disease—KIT—thymus cancer	1.73e-05	0.000186	CbGpPWpGaD
Ponatinib—LYN—Innate Immune System—AKT1—thymus cancer	1.69e-05	0.000182	CbGpPWpGaD
Ponatinib—ABL1—Innate Immune System—AKT1—thymus cancer	1.68e-05	0.000181	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—KIT—thymus cancer	1.67e-05	0.00018	CbGpPWpGaD
Ponatinib—LYN—Adaptive Immune System—AKT1—thymus cancer	1.62e-05	0.000175	CbGpPWpGaD
Ponatinib—LCK—Immune System—CD4—thymus cancer	1.62e-05	0.000174	CbGpPWpGaD
Ponatinib—SRC—Hemostasis—TP53—thymus cancer	1.61e-05	0.000174	CbGpPWpGaD
Ponatinib—FGFR3—Disease—AKT1—thymus cancer	1.61e-05	0.000174	CbGpPWpGaD
Ponatinib—LCK—Hemostasis—AKT1—thymus cancer	1.54e-05	0.000166	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—AKT1—thymus cancer	1.53e-05	0.000165	CbGpPWpGaD
Ponatinib—LCK—Disease—CD4—thymus cancer	1.49e-05	0.000161	CbGpPWpGaD
Ponatinib—LCK—Immune System—IL2—thymus cancer	1.49e-05	0.00016	CbGpPWpGaD
Ponatinib—SRC—Immune System—CD4—thymus cancer	1.43e-05	0.000154	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—IL2—thymus cancer	1.43e-05	0.000154	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—IL2—thymus cancer	1.41e-05	0.000152	CbGpPWpGaD
Ponatinib—SRC—Developmental Biology—AKT1—thymus cancer	1.39e-05	0.00015	CbGpPWpGaD
Ponatinib—LCK—Innate Immune System—AKT1—thymus cancer	1.39e-05	0.000149	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—KIT—thymus cancer	1.37e-05	0.000147	CbGpPWpGaD
Ponatinib—SRC—Hemostasis—AKT1—thymus cancer	1.36e-05	0.000147	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—TP53—thymus cancer	1.34e-05	0.000144	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—IL2—thymus cancer	1.33e-05	0.000144	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—IL2—thymus cancer	1.33e-05	0.000144	CbGpPWpGaD
Ponatinib—LCK—Adaptive Immune System—AKT1—thymus cancer	1.33e-05	0.000143	CbGpPWpGaD
Ponatinib—SRC—Disease—CD4—thymus cancer	1.32e-05	0.000143	CbGpPWpGaD
Ponatinib—SRC—Immune System—IL2—thymus cancer	1.32e-05	0.000142	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—AKT1—thymus cancer	1.23e-05	0.000132	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—KIT—thymus cancer	1.21e-05	0.000131	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—AKT1—thymus cancer	1.2e-05	0.000129	CbGpPWpGaD
Ponatinib—KIT—Immune System—AKT1—thymus cancer	1.18e-05	0.000127	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—AKT1—thymus cancer	1.18e-05	0.000127	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—IL2—thymus cancer	1.17e-05	0.000127	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—TP53—thymus cancer	1.16e-05	0.000126	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—AKT1—thymus cancer	1.13e-05	0.000122	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—AKT1—thymus cancer	1.12e-05	0.000121	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—AKT1—thymus cancer	1.12e-05	0.00012	CbGpPWpGaD
Ponatinib—FGFR2—Disease—AKT1—thymus cancer	1.11e-05	0.00012	CbGpPWpGaD
Ponatinib—KIT—Disease—AKT1—thymus cancer	1.09e-05	0.000117	CbGpPWpGaD
Ponatinib—FGFR1—Disease—AKT1—thymus cancer	1.03e-05	0.000111	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—AKT1—thymus cancer	1.03e-05	0.000111	CbGpPWpGaD
Ponatinib—LYN—Immune System—AKT1—thymus cancer	9.84e-06	0.000106	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—AKT1—thymus cancer	9.83e-06	0.000106	CbGpPWpGaD
Ponatinib—ABL1—Immune System—AKT1—thymus cancer	9.8e-06	0.000106	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—IL2—thymus cancer	9.62e-06	0.000104	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—TP53—thymus cancer	9.19e-06	9.91e-05	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—AKT1—thymus cancer	9.14e-06	9.86e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—TP53—thymus cancer	9.03e-06	9.74e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—TP53—thymus cancer	8.57e-06	9.24e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—TP53—thymus cancer	8.54e-06	9.22e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—IL2—thymus cancer	8.52e-06	9.19e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—AKT1—thymus cancer	8.07e-06	8.7e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—AKT1—thymus cancer	7.76e-06	8.37e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—AKT1—thymus cancer	7.62e-06	8.22e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—TP53—thymus cancer	7.54e-06	8.13e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—AKT1—thymus cancer	7.45e-06	8.03e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—AKT1—thymus cancer	7.23e-06	7.8e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—AKT1—thymus cancer	7.21e-06	7.78e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—AKT1—thymus cancer	7.14e-06	7.7e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—AKT1—thymus cancer	6.59e-06	7.11e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—AKT1—thymus cancer	6.36e-06	6.86e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—TP53—thymus cancer	6.18e-06	6.66e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—AKT1—thymus cancer	6.04e-06	6.52e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—TP53—thymus cancer	5.47e-06	5.9e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—AKT1—thymus cancer	5.22e-06	5.63e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—AKT1—thymus cancer	4.62e-06	4.98e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—AKT1—thymus cancer	4.33e-06	4.67e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—AKT1—thymus cancer	3.75e-06	4.05e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—AKT1—thymus cancer	3.27e-06	3.52e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—AKT1—thymus cancer	3.08e-06	3.32e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—AKT1—thymus cancer	2.01e-06	2.17e-05	CbGpPWpGaD
